by Gemma Escarré,
FreeOx Biotech, spin-out of Hospital Clinic Barcelona-IDIBAPS and member of CataloniaBio & HealthTech, has opened a round of investment hoping to raise €500,000. The company’s goal this year is to accelerate development and the regulatory process for its drug candidate Ox-01, which has completed phase IIb, and begin preclinical trials with Ox-02. Both drugs are being used to treat stroke and other diseases of the central nervous system (CNS).
“We’re looking for a total of €500,000 and we’ve already raised €200,000 from two private investors,” explained Carlos Lurigados, co-founder and CEO of FreeOx. These investors are Ms Montserrat Esteve and Mr Francisco Javier Alsina, the latter from the real estate sector.
Additionally, the company has recently taken on a new strategic partner: Xavier Luria, former executive at the European Medicines Agency (EMA) and founder of DDR consulting.
Photo: From left to right, Dr Angel Chamorro and Carlos Lurigados - © FreeOx Biotech